<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548534</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN11-PB</org_study_id>
    <secondary_id>2011-A01029-32</secondary_id>
    <nct_id>NCT01548534</nct_id>
  </id_info>
  <brief_title>A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer</brief_title>
  <acronym>DHALYA</acronym>
  <official_title>A Phase III Randomized, Multicenter, Two Arms Double-blind Trial Versus Placebo, Evaluating the Interest of a Dietary Supplementation With Docosahexaenoic Acid (DHA) During Chemotherapy for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICO Paul Papin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to increase, by DHA-induced chemosensitization, the activity of
      anticancer chemotherapy in patients with a metastatic advanced breast cancer, by a
      nutritional approach with marin-derived PolyUnsaturated Fatty Acids (PUFA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local relapses and metastases make breast cancer a deadly disease. A major goal remains the
      improvement of treatment efficacy, meaning increasing toxicity to tumor tissue, without
      additional toxicity to non-tumor tissues.

      The literature indicates that DHA sensitizes breast malignant tumors, but not non-tumor
      tissues, to chemotherapy and to radiotherapy through a variety of mechanisms. DHA enrichment
      of tissues can be achieved through a dietary supplementation of DHA-containing oils, such as
      fish oil, both in experimental animal models or in humans. Therefore, this represents an
      original nutritional approach to increase the activity of anticancer treatments through an
      enhanced specificity toward tumor tissues.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Judicial liquidation of the society providing dietary supplementation.
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>4 months</time_frame>
    <description>PFS is defined as time from randomization to disease progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>The objective response is the best objective response observed from the start of treatment to progression.</time_frame>
    <description>ORR will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years after last chemotherapy in study</time_frame>
    <description>OS is defined as time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>First progression</time_frame>
    <description>TTP is defined as time from randomization to first documentation of objective tumor progression according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety ans tolerance of dietary supplementation/chemotherapy association</measure>
    <time_frame>4 months</time_frame>
    <description>Incidence and severity of adverse events will be assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary supplementation compliance</measure>
    <time_frame>4 months</time_frame>
    <description>Compliance will be assessed through patient's diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life (QOL)</measure>
    <time_frame>At C1, after 4 months of chemotherapy, and at the end of chemotherapy.</time_frame>
    <description>QOL will be assessed by QLQ-C30 and BR23 questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Pain will be assessed by a Visual Analog Scale (VAS) and analgesic consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHA plasma level</measure>
    <time_frame>Before dietary supplementation (at C1), and after 4 months of dietary supplementation.</time_frame>
    <description>Plasma phospholipids DHA incorporation will be measured with a blood sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Neuropathy will be assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Progesterone Receptor Positive Tumor</condition>
  <condition>Estrogen Receptor Positive Tumor</condition>
  <condition>HER-2 Negative Tumor</condition>
  <arm_group>
    <arm_group_label>DHA-free arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary supplementation with vegetable oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary supplementation with fish oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary supplementation with fish oil.</intervention_name>
    <description>Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.</description>
    <arm_group_label>DHA arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary supplementation with vegetable oil</intervention_name>
    <description>Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.</description>
    <arm_group_label>DHA-free arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic breast cancer requiring first-line taxanes or anthracyclines based
             chemotherapy

          -  HER2 negative, HR positive

          -  Life expectancy &gt; 3 months

          -  ECOG Performance Status &lt; or = 2 within 15 days before randomization

          -  Measurable and/or evaluable disease according to RECIST criteria 1.1

          -  Age &gt; or = 18 years and &lt; or = 80 years

          -  Body Mass Index (BMI)&gt;17 for patients &lt; 70 years and BMI&gt;21 for patients &gt; 70 years,
             within 15 days before randomization

          -  Hepatic parameters : total bilirubin strictly normal, AST and ALT &lt; or = 3xULN (5 if
             liver metastases) within 15 days before randomization

          -  Signed written informed consent

        Exclusion Criteria:

          -  Triple negative breast cancer or HER2 over expression

          -  Symptomatic central nervous system metastases

          -  Previous chemotherapy for metastatic breast cancer

          -  Obesity with BMI &gt; 35 within 15 days before randomization

          -  Presence of another invasive cancer

          -  Uncontrolled Cardiac disease or uncontrolled hypertension

          -  Milk protein intolerance

          -  Known food allergy to fish

          -  Women of childbearing potential not using adequate contraceptive measures, pregnant or
             breast feeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Bougnoux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Canc√©rologie de l'Ouest (ICO)</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jacques Coeur</name>
      <address>
        <city>Bourges</city>
        <zip>18016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Cholet</city>
        <zip>49325</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D√©partemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Guillaume de Varye</name>
      <address>
        <city>St Doulchard</city>
        <zip>18230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Priv√©</name>
      <address>
        <city>St Gr√©goire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>First-Line chemotherapy</keyword>
  <keyword>Taxane or Anthracycline</keyword>
  <keyword>DHA</keyword>
  <keyword>PUFA</keyword>
  <keyword>Dietary supplementation</keyword>
  <keyword>First-Line Taxane or Anthracycline based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

